:@0.914624:0.081813:0.920519:0.081813:0.920519:0.063369:0.914624:0.063369:0.005895
 :@0.884977:0.970453:0.890322:0.970453:0.890322:0.952432:0.884977:0.952432:0.005345
P-23  Phenotypic and Genetic Characteristics of :@0.242066:0.104825:0.763843:0.104825:0.763843:0.086058:0.242066:0.086058:0.015821:0.007982:0.013255:0.013113:0.006617:0.016045:0.015876:0.013234:0.013234:0.013234:0.013234:0.006617:0.011806:0.013234:0.005284:0.011949:0.006617:0.013044:0.013234:0.013234:0.006617:0.018519:0.013234:0.013115:0.013234:0.006617:0.005284:0.011901:0.006617:0.017066:0.013234:0.013234:0.007998:0.013115:0.011901:0.006617:0.013115:0.007926:0.005284:0.011997:0.006617:0.005070:0.011901:0.011901:0.006617:0.013234:0.006522:0.006617
Mucopolysaccharidosis Type II Patients: A Single :@0.314899:0.125687:0.840440:0.125687:0.840440:0.106920:0.314899:0.106920:0.019828:0.013234:0.011949:0.013115:0.013234:0.013234:0.005165:0.011901:0.011901:0.013234:0.011901:0.011901:0.013234:0.013163:0.007926:0.005284:0.013234:0.013234:0.011901:0.005141:0.011901:0.006617:0.014543:0.011901:0.013234:0.013234:0.006522:0.006617:0.006498:0.006617:0.015757:0.013234:0.006617:0.005284:0.013234:0.013234:0.006617:0.011901:0.006617:0.006498:0.015876:0.006498:0.015876:0.005284:0.013234:0.013234:0.005284:0.013234:0.006617
Centre Retrospective Study in Malaysia :@0.314899:0.146584:0.737471:0.146584:0.737471:0.127817:0.314899:0.127817:0.017185:0.013282:0.013234:0.006617:0.007807:0.013234:0.006617:0.017185:0.013234:0.006450:0.007926:0.013234:0.011901:0.013234:0.013139:0.011901:0.006617:0.005284:0.011901:0.013234:0.006498:0.015876:0.006498:0.013234:0.013234:0.011997:0.006617:0.005284:0.013234:0.006498:0.019828:0.013234:0.005284:0.013115:0.011901:0.012020:0.005141:0.013235:0.006617
 :@0.906214:0.104825:0.912832:0.104825:0.912832:0.086058:0.906214:0.086058:0.006617
P-24  Revolutionizing Aptamer Development: :@0.242066:0.173292:0.732185:0.173292:0.732185:0.154525:0.242066:0.154525:0.015821:0.007982:0.013255:0.013113:0.006617:0.016045:0.017185:0.013234:0.011901:0.013234:0.005284:0.013234:0.006617:0.005284:0.013092:0.013234:0.005284:0.011949:0.005141:0.013234:0.013234:0.006617:0.015805:0.013234:0.006617:0.013234:0.019828:0.013234:0.007926:0.006450:0.017185:0.013234:0.011901:0.013234:0.005284:0.013139:0.013234:0.019828:0.013234:0.013234:0.006450:0.006617:0.006617
Electrochemical-based SELEX for Rapid Target :@0.314899:0.194155:0.823213:0.194155:0.823213:0.175388:0.314899:0.175388:0.015876:0.005284:0.013234:0.011901:0.006617:0.007926:0.013139:0.011901:0.013234:0.013234:0.019828:0.005094:0.011901:0.013306:0.005282:0.007839:0.013234:0.013139:0.011901:0.013306:0.013234:0.006617:0.015781:0.015686:0.013234:0.015876:0.015781:0.006617:0.006498:0.013234:0.007974:0.006617:0.017185:0.013234:0.013234:0.005165:0.013234:0.006617:0.014543:0.013234:0.007926:0.013139:0.013234:0.006617:0.006617
Binding :@0.314899:0.214917:0.400764:0.214917:0.400764:0.196150:0.314899:0.196150:0.015876:0.005284:0.013234:0.013234:0.005284:0.013234:0.013100:0.006617
 :@0.906214:0.173292:0.912832:0.173292:0.912832:0.154525:0.906214:0.154525:0.006617
P-25  Manufacturing and Validation of current Good :@0.242066:0.241726:0.800975:0.241726:0.800975:0.222959:0.242066:0.222959:0.015821:0.007982:0.013255:0.013113:0.006617:0.016045:0.019828:0.013234:0.013234:0.013234:0.006617:0.013092:0.011901:0.006617:0.013234:0.007998:0.005141:0.013115:0.013234:0.006617:0.013234:0.013234:0.013234:0.006617:0.015781:0.013234:0.005284:0.005284:0.013234:0.013234:0.006617:0.005118:0.013234:0.013234:0.006617:0.013234:0.006617:0.006498:0.011901:0.013234:0.007926:0.007926:0.013234:0.013234:0.006522:0.006617:0.018519:0.013234:0.013234:0.013234:0.006617
Manufacturing Practices (cGMP)-Compliant Umbilical :@0.314899:0.262488:0.882559:0.262488:0.882559:0.243721:0.314899:0.243721:0.019828:0.013234:0.013234:0.013234:0.006617:0.013092:0.011901:0.006617:0.013234:0.007998:0.005141:0.013115:0.013234:0.006617:0.015781:0.007926:0.013282:0.011901:0.006617:0.005141:0.011901:0.013234:0.011901:0.006617:0.007807:0.011901:0.018519:0.019756:0.015876:0.008001:0.007839:0.017185:0.013234:0.019756:0.013234:0.005284:0.005141:0.013234:0.013234:0.006617:0.006546:0.017185:0.019828:0.013234:0.005284:0.005284:0.005165:0.011901:0.013306:0.005284:0.006617
Cord-Derived Mesenchymal Stromal Cells (UCMSC) :@0.314899:0.283350:0.873502:0.283350:0.873502:0.264584:0.314899:0.264584:0.017185:0.013282:0.007831:0.013298:0.007839:0.017185:0.013234:0.007926:0.005284:0.011806:0.013234:0.013139:0.006617:0.019756:0.013234:0.011973:0.013234:0.013139:0.011901:0.013234:0.011901:0.019685:0.013234:0.005284:0.006617:0.015781:0.006617:0.007926:0.013234:0.019828:0.013234:0.005284:0.006617:0.017185:0.013115:0.005284:0.005284:0.011901:0.006617:0.007926:0.017185:0.017185:0.019828:0.015686:0.017185:0.008021:0.006617
for Clinical Application :@0.314899:0.304213:0.555173:0.304213:0.555173:0.285446:0.314899:0.285446:0.006617:0.013234:0.007926:0.006617:0.017185:0.005284:0.005284:0.013234:0.005141:0.011901:0.013306:0.005284:0.006617:0.015615:0.013234:0.013234:0.005284:0.005284:0.011901:0.013234:0.006522:0.005284:0.013234:0.013196:0.006617
 :@0.906214:0.241726:0.912832:0.241726:0.912832:0.222959:0.906214:0.222959:0.006617
P-26  Quantitative Analysis of TNF-α Levels in Plasma: :@0.242066:0.330922:0.837108:0.330922:0.837108:0.312155:0.242066:0.312155:0.015821:0.007982:0.013255:0.013113:0.006617:0.016045:0.018519:0.013234:0.013234:0.013282:0.006617:0.005284:0.006474:0.013234:0.006617:0.005284:0.011782:0.013234:0.006617:0.015781:0.013234:0.013234:0.005284:0.011901:0.011901:0.005284:0.011973:0.006617:0.013234:0.006522:0.006617:0.014329:0.017185:0.014703:0.007839:0.013758:0.006617:0.013234:0.013139:0.011901:0.013306:0.005141:0.011901:0.006617:0.005141:0.013234:0.006617:0.015781:0.005284:0.013234:0.011949:0.019828:0.013234:0.006617:0.006617
Evaluating the Impact of Different Celastrol Doses in :@0.314899:0.351784:0.872169:0.351784:0.872169:0.333017:0.314899:0.333017:0.015876:0.011901:0.013234:0.005284:0.013234:0.013234:0.006617:0.005284:0.013115:0.013234:0.006617:0.006522:0.013234:0.013234:0.006617:0.006546:0.019828:0.013234:0.013234:0.011973:0.006617:0.006498:0.013234:0.006617:0.006522:0.017114:0.005284:0.006617:0.006474:0.013234:0.007974:0.013234:0.013234:0.006617:0.006546:0.017185:0.013282:0.005284:0.013092:0.011901:0.006474:0.007926:0.013282:0.005284:0.006617:0.017185:0.013092:0.011901:0.013234:0.011901:0.006617:0.005284:0.013234:0.006617
High-Fat Diet-Fed ApoE-Knockout Mice Using ELISA :@0.314899:0.372647:0.880049:0.372647:0.880049:0.353880:0.314899:0.353880:0.017185:0.005284:0.013234:0.013184:0.007982:0.014543:0.013234:0.006617:0.006522:0.017185:0.005189:0.013234:0.006570:0.007982:0.014543:0.013234:0.013234:0.006617:0.015805:0.013234:0.013234:0.015760:0.007982:0.015686:0.013234:0.013234:0.011901:0.011901:0.013163:0.013234:0.006617:0.006522:0.019828:0.005284:0.011901:0.013163:0.006617:0.017185:0.011901:0.005284:0.013234:0.013234:0.006522:0.015876:0.013234:0.006522:0.015876:0.015782:0.006617
 :@0.906214:0.330922:0.912832:0.330922:0.912832:0.312155:0.906214:0.312155:0.006617
P-27  Detection Of Large Deletions And Duplication In :@0.242066:0.399355:0.826016:0.399355:0.826016:0.380588:0.242066:0.380588:0.015821:0.007982:0.013255:0.013113:0.006617:0.016045:0.017185:0.013282:0.006617:0.013044:0.011901:0.006617:0.005284:0.013234:0.013234:0.006617:0.018519:0.006617:0.006498:0.013234:0.013234:0.007998:0.013115:0.013234:0.006617:0.017185:0.013234:0.005165:0.013234:0.006617:0.005284:0.013068:0.013234:0.011973:0.006617:0.015757:0.013234:0.013234:0.006617:0.017090:0.013234:0.013234:0.005284:0.005165:0.011901:0.013306:0.006617:0.005284:0.013234:0.013234:0.006522:0.006617:0.013234:0.006617
F8:@0.826064:0.399322:0.853837:0.399322:0.853837:0.380588:0.826064:0.380588:0.014538:0.013234
 :@0.853905:0.399355:0.860523:0.399355:0.860523:0.380588:0.853905:0.380588:0.006617
Gene Of Haemophilia A Patients :@0.314899:0.420252:0.664922:0.420252:0.664922:0.401485:0.314899:0.401485:0.018519:0.013234:0.013234:0.013282:0.006617:0.018519:0.006498:0.006617:0.017043:0.013234:0.013139:0.019828:0.013234:0.013234:0.013234:0.005284:0.005284:0.005284:0.013234:0.006617:0.015805:0.006617:0.015757:0.013234:0.006617:0.005284:0.013234:0.013234:0.006617:0.011833:0.006617
 :@0.906214:0.399355:0.912832:0.399355:0.912832:0.380588:0.906214:0.380588:0.006617
P-28  Frequency Of Anti-Acetylcholine Receptor (AChR) :@0.242066:0.446960:0.849752:0.446960:0.849752:0.428193:0.242066:0.428193:0.015821:0.007982:0.013255:0.013113:0.006617:0.016045:0.014543:0.007926:0.013234:0.013234:0.013234:0.013234:0.013115:0.011901:0.011901:0.006617:0.018519:0.006498:0.006617:0.015757:0.013234:0.006617:0.005282:0.007982:0.015876:0.011901:0.013234:0.006617:0.011901:0.005189:0.011901:0.013234:0.013234:0.005284:0.005284:0.013234:0.013234:0.006617:0.017043:0.013234:0.011901:0.013234:0.013234:0.006617:0.013044:0.007926:0.006617:0.007926:0.015876:0.017185:0.013234:0.017043:0.007926:0.006617
Antibody Among Suspected Myasthenia Gravis :@0.314899:0.467823:0.818042:0.467823:0.818042:0.449056:0.314899:0.449056:0.015876:0.013234:0.006522:0.005284:0.013234:0.013234:0.013234:0.011997:0.006617:0.015757:0.019661:0.013234:0.013234:0.013234:0.006617:0.015876:0.013234:0.011806:0.013234:0.013139:0.011901:0.006617:0.013115:0.013234:0.006617:0.019828:0.011901:0.013139:0.011901:0.006617:0.013234:0.013234:0.013282:0.005141:0.013115:0.006617:0.018519:0.007926:0.013115:0.011901:0.005284:0.012020:0.006617
Patients In Malaysia :@0.314899:0.488685:0.534221:0.488685:0.534221:0.469919:0.314899:0.469919:0.015876:0.013234:0.006522:0.005284:0.013234:0.013234:0.006617:0.011901:0.006617:0.006546:0.013234:0.006617:0.019828:0.013234:0.005284:0.013234:0.011806:0.011901:0.005284:0.013214:0.006617
 :@0.906214:0.446960:0.912832:0.446960:0.912832:0.428193:0.906214:0.428193:0.006617
P-29  Advancing Biochemical Diagnosis of Aromatic-L-:@0.242066:0.515394:0.827434:0.515394:0.827434:0.496627:0.242066:0.496627:0.015821:0.007982:0.013255:0.013113:0.006617:0.016045:0.015876:0.013234:0.011901:0.013234:0.013234:0.011901:0.005284:0.013115:0.013234:0.006617:0.015781:0.005284:0.013234:0.011949:0.013115:0.013234:0.019828:0.005284:0.011830:0.013234:0.005284:0.006617:0.017185:0.005141:0.013234:0.013234:0.013234:0.013234:0.011901:0.005141:0.011901:0.006617:0.013234:0.006617:0.006600:0.015876:0.007926:0.013234:0.019828:0.013234:0.006617:0.005284:0.011785:0.007982:0.013255:0.007926
Amino Acid Decarboxylase Deficiency (AADC-D): :@0.314899:0.536256:0.841819:0.536256:0.841819:0.517490:0.314899:0.517490:0.015876:0.019828:0.005213:0.013234:0.013234:0.006617:0.015805:0.011901:0.005284:0.013282:0.006617:0.017043:0.013234:0.011973:0.013115:0.007926:0.013282:0.013115:0.011901:0.011901:0.005284:0.013092:0.011901:0.013234:0.006498:0.017185:0.013282:0.006617:0.005284:0.011901:0.005284:0.013092:0.013234:0.011901:0.011901:0.006617:0.007807:0.015876:0.015757:0.017185:0.017486:0.007839:0.017114:0.007926:0.006617:0.006617
HPLC-Based AADC Activity Assay Preceding Genetic :@0.314899:0.557018:0.887784:0.557018:0.887784:0.538252:0.314899:0.538252:0.017185:0.015876:0.013234:0.017130:0.007982:0.015876:0.013068:0.011901:0.013306:0.013234:0.006427:0.015876:0.015757:0.017185:0.017281:0.006617:0.015757:0.011901:0.006617:0.005141:0.011901:0.005284:0.006617:0.011901:0.006617:0.015876:0.011782:0.011901:0.013234:0.011901:0.006617:0.015781:0.007926:0.013234:0.011759:0.013234:0.013234:0.005284:0.013234:0.013282:0.006617:0.018328:0.013234:0.013234:0.013234:0.006617:0.005141:0.011901:0.006617
Testing :@0.314899:0.577881:0.399481:0.577881:0.399481:0.559114:0.314899:0.559114:0.014543:0.013234:0.011973:0.006617:0.005284:0.013234:0.013078:0.006617
 :@0.906214:0.515394:0.912832:0.515394:0.912832:0.496627:0.906214:0.496627:0.006617
P-30  Colorimetric Aptablot Assay for the Detection of :@0.242066:0.604589:0.820517:0.604589:0.820517:0.585823:0.242066:0.585823:0.015821:0.007982:0.013255:0.013113:0.006617:0.016045:0.017185:0.013282:0.005284:0.013092:0.007926:0.005284:0.019828:0.013234:0.006617:0.007926:0.005165:0.011901:0.006474:0.015876:0.013234:0.006522:0.013234:0.013234:0.005284:0.013234:0.006617:0.006617:0.015757:0.011901:0.011901:0.013234:0.011973:0.006617:0.006498:0.013234:0.007974:0.006617:0.006498:0.013234:0.013234:0.006450:0.017185:0.013282:0.006403:0.013234:0.011973:0.006617:0.005284:0.013234:0.013234:0.006522:0.013234:0.006617:0.006617
Chikungunya Virus (CHIKV)   :@0.314899:0.625452:0.629147:0.625452:0.629147:0.606685:0.314899:0.606685:0.017185:0.013282:0.005141:0.011901:0.013306:0.013115:0.013234:0.013234:0.013163:0.011901:0.013306:0.006403:0.015876:0.005284:0.007926:0.013234:0.011949:0.006617:0.007783:0.017114:0.017185:0.006617:0.015876:0.015757:0.007926:0.006617:0.006692:0.006617
 :@0.906214:0.604589:0.912832:0.604589:0.912832:0.585823:0.906214:0.585823:0.006617
P-31  Discovery of Ten Novel Germline RB1 Gene :@0.242066:0.652161:0.787598:0.652161:0.787598:0.633394:0.242066:0.633394:0.015821:0.007982:0.013255:0.013113:0.006617:0.016045:0.017185:0.005284:0.011901:0.011901:0.013234:0.011901:0.013115:0.007926:0.011997:0.006617:0.013234:0.006522:0.006403:0.014543:0.013234:0.013234:0.006617:0.017185:0.013139:0.011901:0.013306:0.005284:0.006617:0.018304:0.013234:0.007974:0.019828:0.005284:0.005284:0.013068:0.013234:0.006617:0.017185:0.015876:0.013234:0.006403:0.018519:0.013234:0.013234:0.013282:0.006617
Mutations in Unrelated Malaysian Patients with :@0.314899:0.673023:0.814043:0.673023:0.814043:0.654256:0.314899:0.654256:0.019828:0.013234:0.006617:0.013234:0.006522:0.005284:0.013234:0.013234:0.011973:0.006617:0.005284:0.013234:0.006355:0.017185:0.013282:0.007831:0.013234:0.005284:0.013234:0.006617:0.013234:0.013234:0.006617:0.019614:0.013115:0.005284:0.013234:0.011901:0.011901:0.005284:0.013234:0.013234:0.006617:0.015805:0.013234:0.006617:0.005284:0.013068:0.013234:0.006617:0.011901:0.006617:0.017185:0.005284:0.006617:0.013234:0.006617
Retinoblastoma: A 12-Year Experience :@0.314899:0.693920:0.732197:0.693920:0.732197:0.675153:0.314899:0.675153:0.017185:0.013282:0.006617:0.005284:0.013234:0.013068:0.013234:0.005284:0.013115:0.011901:0.006617:0.013115:0.019828:0.013234:0.006617:0.006498:0.015876:0.006498:0.013234:0.013375:0.007982:0.015876:0.013234:0.013068:0.007926:0.006617:0.015876:0.011901:0.013234:0.013139:0.007926:0.005284:0.013234:0.013234:0.011901:0.013145:0.006617
 :@0.906214:0.652161:0.912832:0.652161:0.912832:0.633394:0.906214:0.633394:0.006617
P-32  The effect of lauric acid-rich diets in the immune :@0.242066:0.720628:0.826103:0.720628:0.826103:0.701861:0.242066:0.701861:0.015821:0.007982:0.013255:0.013113:0.006617:0.016045:0.014543:0.013234:0.013234:0.006617:0.013234:0.006617:0.006498:0.013234:0.011973:0.006617:0.006498:0.013234:0.006617:0.006522:0.005284:0.013234:0.013234:0.007998:0.005141:0.011901:0.006617:0.013234:0.011973:0.005141:0.013338:0.007839:0.007926:0.005284:0.011901:0.013234:0.006617:0.013234:0.005284:0.013234:0.006522:0.011901:0.006617:0.005284:0.013234:0.006617:0.006522:0.013234:0.013234:0.006450:0.005284:0.019828:0.019828:0.013234:0.013234:0.013234:0.006617
system: A flow cytometer analysis :@0.314899:0.741491:0.678035:0.741491:0.678035:0.722724:0.314899:0.722724:0.011901:0.011901:0.011901:0.006617:0.013234:0.019828:0.006617:0.006522:0.015876:0.006498:0.006617:0.005284:0.013234:0.017185:0.006617:0.011782:0.011901:0.006617:0.013234:0.019828:0.013234:0.006617:0.013092:0.007926:0.006617:0.013234:0.013234:0.013234:0.005189:0.011901:0.012020:0.005141:0.011879:0.006617
 :@0.906214:0.720628:0.912832:0.720628:0.912832:0.701861:0.906214:0.701861:0.006617
P-33  Exploring The Positional Distribution of Fatty Acids in :@0.242066:0.768199:0.878715:0.768199:0.878715:0.749432:0.242066:0.749432:0.015821:0.007982:0.013255:0.013113:0.006617:0.016045:0.015876:0.011901:0.013234:0.005284:0.013139:0.007926:0.005284:0.013234:0.013306:0.006617:0.014543:0.013044:0.013234:0.006617:0.015781:0.013234:0.011973:0.005284:0.006617:0.005213:0.013234:0.013234:0.013234:0.005284:0.006474:0.017185:0.005284:0.011997:0.006617:0.007926:0.005118:0.013234:0.013234:0.006617:0.005284:0.013234:0.013234:0.006617:0.013234:0.006379:0.006617:0.014543:0.013234:0.006522:0.006617:0.011901:0.006617:0.015781:0.011901:0.005284:0.013282:0.011901:0.006617:0.005141:0.013234:0.006617
Human Plasma Chylomicrons Using 13C Nuclear :@0.314899:0.789062:0.840554:0.789062:0.840554:0.770295:0.314899:0.770295:0.017185:0.013282:0.019828:0.013092:0.013234:0.006617:0.015781:0.005284:0.013234:0.011901:0.019756:0.013234:0.006612:0.017185:0.013234:0.011901:0.005284:0.013234:0.019828:0.005141:0.011901:0.007926:0.013234:0.013234:0.011973:0.006403:0.017185:0.012020:0.005141:0.013234:0.013234:0.006617:0.013234:0.013115:0.017185:0.006617:0.017185:0.013234:0.011901:0.005284:0.013115:0.013234:0.007974:0.006617
Magnetic Resonance Spectroscopy :@0.314899:0.809924:0.695281:0.809924:0.695281:0.791158:0.314899:0.791158:0.019828:0.013234:0.013234:0.013234:0.013234:0.006617:0.005141:0.011901:0.006617:0.017185:0.013234:0.011782:0.013234:0.013234:0.013234:0.013234:0.011901:0.013234:0.006617:0.015805:0.013234:0.013139:0.011901:0.006474:0.007926:0.013282:0.011901:0.011901:0.013115:0.013234:0.011916:0.006617
 :@0.906214:0.768199:0.912832:0.768199:0.912832:0.749432:0.906214:0.749432:0.006617
P-34  Influence of Palm Olein on Human Gut Microbiota and   :@0.242066:0.836633:0.912832:0.836633:0.912832:0.817866:0.242066:0.817866:0.015821:0.007982:0.013255:0.013113:0.006617:0.016045:0.006617:0.013234:0.006522:0.005284:0.013234:0.013234:0.013234:0.011901:0.013234:0.006617:0.013234:0.006522:0.006617:0.015757:0.013234:0.005284:0.019828:0.006617:0.018519:0.005284:0.013234:0.005284:0.013234:0.006522:0.013234:0.013234:0.006450:0.017185:0.013282:0.019828:0.013092:0.013234:0.006617:0.018519:0.013234:0.006617:0.006355:0.019828:0.005284:0.011901:0.007926:0.013234:0.013234:0.005284:0.013234:0.006617:0.013234:0.006522:0.013115:0.013115:0.013234:0.006617:0.015765:0.006617
Gut-Fermented Short Chain Fatty Acids :@0.314899:0.857495:0.738753:0.857495:0.738753:0.838729:0.314899:0.838729:0.018529:0.013245:0.006567:0.007982:0.014543:0.013115:0.007926:0.019828:0.013163:0.013234:0.006617:0.013234:0.013234:0.006617:0.015757:0.013234:0.013234:0.007998:0.006617:0.006498:0.017114:0.013234:0.013234:0.005165:0.013234:0.006617:0.014543:0.013234:0.006522:0.006617:0.011901:0.006617:0.015781:0.011901:0.005284:0.013234:0.011826:0.006617
Organizing Committee :@0.242066:0.887026:0.485000:0.887026:0.485000:0.868259:0.242066:0.868259:0.018519:0.007926:0.013306:0.013115:0.013234:0.005284:0.011949:0.005141:0.013234:0.013234:0.006617:0.017090:0.013234:0.019828:0.019828:0.005284:0.006546:0.006617:0.013234:0.013095:0.006617
 :@0.906214:0.884204:0.912832:0.884204:0.912832:0.865437:0.906214:0.865437:0.006617